Dafinchi AI

SIBN

Healthcare

Adjusted EBITDA was positive $1 million for the quarter, marking the third consecutive quarter of positive adjusted EBITDA.
Gross profit increased by $7.2 million or 22.9% to $38.8 million, with gross margin expanding by 80 basis points to 79.8%.
International revenue was $2.2 million, impacted by later-than-expected regulatory clearance for TORQ in Europe.
Net loss narrowed to $6.2 million or $0.14 per diluted share from $8.9 million or $0.22 per diluted share in the prior year.
Operating expenses rose 10% to $45.8 million, mainly due to growth investments, higher commissions, and elevated G&A spending.
SI-BONE reported worldwide revenue of $48.6 million for Q2 2025, representing 21.7% growth year-over-year.
The company achieved cash flow breakeven in Q2 2025, an important milestone reached ahead of schedule.
Trailing 12-month adjusted EBITDA was positive $3.1 million compared to a loss of $15.4 million in the prior year period.
U.S. revenue, which accounts for 95% of the business, grew 22.8% driven by a 25% increase in procedure volumes.

BNGO

Healthcare

Cash and equivalents totaled $27.4 million at quarter-end, with $11 million subject to restrictions.
Consumables and software revenue grew 16% year-over-year in Q2 and represented 73% of total product revenue, up from 55% last year.
Flowcell sales increased 17% year-over-year to 7,233 units, indicating strong utilization growth.
Installed base of optical genome mapping systems was 378, a 4% increase from 363 systems a year ago, with a net decrease of 1 system in the quarter.
Non-GAAP gross margin improved significantly to 52% from 35% a year ago, driven by cost reductions and manufacturing improvements.
Non-GAAP operating expenses decreased 53% year-over-year to $8.8 million, reflecting substantial cost-cutting and headcount reduction.
Total revenue for Q2 2025 was $6.7 million, down 13% year-over-year, or 5% when excluding $700,000 from discontinued services.

Earnings Feed